Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH MORAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1982699641
CMS profile
180733
Location
STATESVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,765.50

146 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,765.50 146

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH MORAN

NPI 1982699641 · CMS profile ID 180733

Allopathic & Osteopathic Physicians / Internal Medicine

STATESVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982699641?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH MORAN, NPI 1982699641, CMS profile ID 180733. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982699641?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOSEPH MORAN, NPI 1982699641, CMS profile ID 180733. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982699641?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOSEPH MORAN, NPI 1982699641, CMS profile ID 180733, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1982699641?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

146 matching records · $1,765.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 146 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–146 of 146.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $14.5104/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682044727 CMS
PFIZER INC. $14.3104/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672371935 CMS
PFIZER INC. $12.9304/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672382907 CMS
Teva Pharmaceuticals USA, Inc. $10.9204/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697701939 CMS
SANOFI-AVENTIS U.S. LLC $15.0404/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694011773 CMS
Mannkind Corporation $19.3504/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705574111 CMS
Amgen Inc. $9.3604/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662567797 CMS
SANOFI-AVENTIS U.S. LLC $14.0304/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694012915 CMS
Astellas Pharma US Inc $12.5204/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655699133 CMS
Novo Nordisk Inc $10.8704/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669520081 CMS
Novo Nordisk Inc $8.0204/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682877087 CMS
Aytu BioScience, Inc $12.5304/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668009855 CMS
Amarin Pharma Inc. $10.8503/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699111363 CMS
PFIZER INC. $11.3403/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672332979 CMS
Amgen Inc. $9.7803/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662567783 CMS
Supernus Pharmaceuticals, Inc. $12.4203/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702335729 CMS
Supernus Pharmaceuticals, Inc. $22.0903/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702335731 CMS
Novo Nordisk Inc $7.4103/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682877081 CMS
Novartis Pharmaceuticals Corporation $12.1403/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659855367 CMS
Amgen Inc. $19.0603/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662567793 CMS
PFIZER INC. $20.2703/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672327707 CMS
Novo Nordisk Inc $6.7203/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682877085 CMS
Aytu BioScience, Inc $11.3602/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668009853 CMS
PFIZER INC. $13.0702/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672284161 CMS
PFIZER INC. $3.5002/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672309869 CMS
PFIZER INC. $10.2702/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672311899 CMS
SANOFI-AVENTIS U.S. LLC $10.6802/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693922505 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.7502/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681778399 CMS
Astellas Pharma US Inc $12.5402/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655699129 CMS
Novo Nordisk Inc $9.7302/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682877077 CMS
Mylan Specialty L.P. $14.0402/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694773385 CMS
SANOFI-AVENTIS U.S. LLC $12.0802/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693924669 CMS
Aytu BioScience, Inc $10.3102/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668009851 CMS
PFIZER INC. $2.9102/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672352945 CMS
PFIZER INC. $10.8602/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672381841 CMS
Merck Sharp & Dohme Corporation $13.4902/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695248955 CMS
Aytu BioScience, Inc $10.4801/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668009849 CMS
PFIZER INC. $12.8101/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672361239 CMS
Novo Nordisk Inc $8.2001/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682877073 CMS
Amgen Inc. $17.8701/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662567779 CMS
Amgen Inc. $22.7101/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662567789 CMS
Novo Nordisk Inc $7.6401/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682877071 CMS
PFIZER INC. $12.1001/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672310247 CMS
Merck Sharp & Dohme Corporation $11.0201/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695217023 CMS
PFIZER INC. $13.0901/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672286639 CMS
Astellas Pharma US Inc $12.8801/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655699126 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,765.50 146
PY2020 $393.77 30
PY2021 $433.14 39
PY2022 $533.43 55
PY2023 $486.57 33
PY2024 $13,183.37 58
PY2025 $1,753.18 62

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $167.39 1
PY2025 Principal investigator $2,732,770.47 231
PY2024 Recipient $13,899.03 12
PY2024 Principal investigator $714,149.85 64
PY2023 Recipient $1,784.16 2
PY2023 Principal investigator $1,338,535.80 60
PY2022 Principal investigator $1,051,629.72 35
PY2021 Principal investigator $222,585.89 253
PY2020 Principal investigator $192,551.38 69
PY2019 Principal investigator $407,918.88 169

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

232 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $20,900.00 12/31/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228805832
Principal investigator 1 Genentech, Inc. $169.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568748
Principal investigator 1 Genentech, Inc. $8,189.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568826
Principal investigator 1 Genentech, Inc. $9,405.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568858
Principal investigator 1 Genentech, Inc. $616.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568952
Principal investigator 1 Hoffmann-La Roche Limited $21,031.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569370
Principal investigator 1 Hoffmann-La Roche Limited $4,536.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211569510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $587.25 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278884
Principal investigator 1 Genentech, Inc. $2,154.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274418
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,025.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,600.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274520
Principal investigator 1 Genentech, Inc. $25,357.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568785
Principal investigator 1 Hoffmann-La Roche Limited $9,186.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569346
Principal investigator 1 Hoffmann-La Roche Limited $500.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569433
Principal investigator 1 Hoffmann-La Roche Limited $15,878.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211569506
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,425.92 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269463
Principal investigator 1 Amgen Inc. $48,124.55 11/25/2025 Non-covered Recipient Entity
ACELLACARE US INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638825
Principal investigator 1 Genentech, Inc. $2,083.00 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211567695
Principal investigator 1 Genentech, Inc. $49,906.00 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,932.87 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184264461
Principal investigator 1 Genentech, Inc. $183.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568023
Principal investigator 1 Genentech, Inc. $5,613.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568229
Principal investigator 1 Genentech, Inc. $500.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568326
Principal investigator 1 Genentech, Inc. $13,496.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568546
Principal investigator 1 Hoffmann-La Roche Limited $19,538.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569272
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $399.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,737.85 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $141.75 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263569
Principal investigator 1 Genentech, Inc. $136.63 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211567853
Principal investigator 1 Genentech, Inc. $7,897.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568188
Principal investigator 1 Hoffmann-La Roche Limited $41,118.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $587.25 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261253
Principal investigator 1 Genentech, Inc. $12,320.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211567654
Principal investigator 1 Genentech, Inc. $7,639.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567707
Principal investigator 1 Genentech, Inc. $12,948.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211567764
Principal investigator 1 Genentech, Inc. $29,503.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567814
Principal investigator 1 Genentech, Inc. $4,248.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211567823
Principal investigator 1 Genentech, Inc. $61.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567827
Principal investigator 1 Genentech, Inc. $9,189.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567834
Principal investigator 1 Genentech, Inc. $27,567.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567906
Principal investigator 1 Genentech, Inc. $183.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567911
Principal investigator 1 Genentech, Inc. $10,120.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567919
Principal investigator 1 Genentech, Inc. $12,389.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567951
Principal investigator 1 Genentech, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567957
Principal investigator 1 Genentech, Inc. $130,185.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567961
Principal investigator 1 Genentech, Inc. $10,709.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568102
Principal investigator 1 Genentech, Inc. $5,203.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211568118
Principal investigator 1 Genentech, Inc. $4,000.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211568138
Principal investigator 1 Genentech, Inc. $6,126.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568145
Principal investigator 1 Genentech, Inc. $17,818.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568236
Principal investigator 1 Genentech, Inc. $7,839.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568287
Principal investigator 1 Genentech, Inc. $7,794.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568370
Principal investigator 1 Genentech, Inc. $23,734.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568468
Principal investigator 1 Genentech, Inc. $14,459.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568527
Principal investigator 1 Genentech, Inc. $18,491.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211568531
Principal investigator 1 Genentech, Inc. $23,186.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211568625
Principal investigator 1 Hoffmann-La Roche Limited $12,320.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569070
Principal investigator 1 Hoffmann-La Roche Limited $105.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569111
Principal investigator 1 Hoffmann-La Roche Limited $75,606.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569116
Principal investigator 1 Hoffmann-La Roche Limited $507.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569130
Principal investigator 1 Hoffmann-La Roche Limited $9,930.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569199
Principal investigator 1 Hoffmann-La Roche Limited $4,000.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569265
Principal investigator 1 Hoffmann-La Roche Limited $362.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,365.44 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,174.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $969.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $284.85 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.52 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,669.70 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $324.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,398.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,356.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,225.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,254.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $528.12 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $513.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $141.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,561.95 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,473.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,080.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,690.95 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,166.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,307.55 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $141.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $324.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $864.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,241.56 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,225.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,398.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,254.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,356.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,025.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,623.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,529.90 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $399.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,949.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $808.65 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,659.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,800.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $540.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,401.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $285.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,100.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,186.08 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,905.07 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,118.69 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,538.90 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,493.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259177
Principal investigator 1 Amgen Inc. $24,025.00 10/24/2025 Non-covered Recipient Entity
ACELLACARE US INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $170,623.53 10/16/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250585
Principal investigator 1 Amgen Inc. $1,248.84 10/08/2025 Non-covered Recipient Entity
CARDIOVASCULAR ASSOCIATES RESEARCH, LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246640001
Principal investigator 1 Amgen Inc. $2,576.19 10/08/2025 Non-covered Recipient Entity
PGM RESEARCH OF PIEDMONT HEALTHCARE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246646460
Principal investigator 1 Genentech, Inc. $11,252.00 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567230
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,067.39 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,700.00 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235233
Principal investigator 1 Genentech, Inc. $1,833.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566953
Principal investigator 1 Genentech, Inc. $390.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567196
Principal investigator 1 Genentech, Inc. $500.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567461
Principal investigator 1 Genentech, Inc. $500.00 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,625.97 08/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230527
Principal investigator 1 Genentech, Inc. $10,538.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567043
Principal investigator 1 Genentech, Inc. $6,826.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567050
Principal investigator 1 Genentech, Inc. $2,716.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567245
Principal investigator 1 Genentech, Inc. $12,320.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567249
Principal investigator 1 Genentech, Inc. $4,000.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567274
Principal investigator 1 Genentech, Inc. $122.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567278
Principal investigator 1 Genentech, Inc. $10,010.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567392
Principal investigator 1 Genentech, Inc. $19,390.00 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566917
Principal investigator 1 Genentech, Inc. $1,000.00 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211567291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,457.81 08/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228423
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,310.13 08/13/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185551321
Principal investigator 1 Amgen Inc. $14,274.24 08/05/2025 Non-covered Recipient Entity
ACCELLACARE OF PIEDMONT HEALTHCARE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638702
Recipient Eli Lilly and Company $167.39 08/01/2025 Covered Recipient Physician A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187872451
Principal investigator 1 Genentech, Inc. $35,330.00 07/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,067.39 07/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217937
Principal investigator 1 Genentech, Inc. $30,373.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211567327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,118.69 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214458
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $611.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214462
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $611.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214484
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,551.50 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214490
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214502
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $432.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,050.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.38 07/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,693.52 06/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210548
Principal investigator 1 F. Hoffmann-La Roche AG $15,889.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566500
Principal investigator 1 F. Hoffmann-La Roche AG $125.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566377
Principal investigator 1 F. Hoffmann-La Roche AG $1,250.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566479
Principal investigator 1 F. Hoffmann-La Roche AG $6,534.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566601
Principal investigator 1 F. Hoffmann-La Roche AG $2,500.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566608
Principal investigator 1 F. Hoffmann-La Roche AG $500.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566636
Principal investigator 1 F. Hoffmann-La Roche AG $10,108.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566668
Principal investigator 1 F. Hoffmann-La Roche AG $13,345.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $673.38 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206527
Principal investigator 1 AstraZeneca Pharmaceuticals LP $116,903.36 06/06/2025 Non-covered Recipient Entity
INNOVO RESEARCH LLC
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185551313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,541.21 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,067.39 05/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198801
Principal investigator 1 F. Hoffmann-La Roche AG $23,311.00 05/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,313.33 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194941
Principal investigator 1 F. Hoffmann-La Roche AG $12,290.00 05/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,346.76 05/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193815
Principal investigator 1 AstraZeneca Pharmaceuticals LP $188,632.18 05/02/2025 Non-covered Recipient Entity
ACCELLACARE
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185551319
Principal investigator 1 F. Hoffmann-La Roche AG $12,097.00 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,887.11 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190785
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,739.34 04/23/2025 Non-covered Recipient Entity
AVICENNA DM CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185551311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,736.56 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189091
Principal investigator 1 F. Hoffmann-La Roche AG $9,550.00 04/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,528.30 04/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,242.26 04/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184182082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,030.37 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180846
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,103.00 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $684.00 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,296.00 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,050.00 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180894
Principal investigator 1 AstraZeneca Pharmaceuticals LP $312,914.43 03/28/2025 Non-covered Recipient Entity
ACCELLACARE
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1185551315
Principal investigator 1 AstraZeneca Pharmaceuticals LP $46,290.56 03/26/2025 Non-covered Recipient Entity
PMG RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185551309
Principal investigator 1 F. Hoffmann-La Roche AG $16,827.00 03/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566325
Principal investigator 1 F. Hoffmann-La Roche AG $3,387.00 03/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566296
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,077.08 03/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174616
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 03/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174624
Principal investigator 1 F. Hoffmann-La Roche AG $9,596.00 03/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,847.69 03/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,685.26 03/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156778
Principal investigator 1 F. Hoffmann-La Roche AG $23,873.00 02/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,675.14 02/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155370
Principal investigator 1 F. Hoffmann-La Roche AG $27,777.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566318
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $513.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $972.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154150
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,167.45 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $569.70 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.01 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,548.50 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $864.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $513.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154538
Principal investigator 1 F. Hoffmann-La Roche AG $3,441.00 02/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211566328
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,784.53 02/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153012
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,213.73 02/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152490
Principal investigator 1 Eli Lilly and Company $848.42 01/31/2025 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187889290
Principal investigator 1 Eli Lilly and Company $465.00 01/31/2025 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187890398
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,491.88 01/29/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149838
Principal investigator 1 Eli Lilly and Company $65,843.00 01/21/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187888788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,002.88 01/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,988.03 01/17/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,224.28 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,766.63 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184146190
Principal investigator 1 Eli Lilly and Company $18,524.00 01/06/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187887618
Principal investigator 1 AstraZeneca Pharmaceuticals LP $163,487.64 01/03/2025 Non-covered Recipient Entity
INNOVO RESEARCH LLC
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185551317